Introduction
============

Use of molecular imaging biomarkers such as amyloid-β PET significantly improves the clinical diagnosis of Alzheimer's dementia ([@awy099-B41]; [@awy099-B4]). However, amyloid-β PET is insufficient as surrogate marker for the prediction of neurodegenerative progression and cognitive deterioration. This is because a substantial number of elderly, apparently healthy subjects with significant amyloid-β plaque load do not develop frank dementia ([@awy099-B1]; [@awy099-B57]). Thus, there is a need for PET biomarkers of disease progression with close associations to cognitive dysfunction that may aid to predict further cognitive decline and neurodegeneration in mild Alzheimer's dementia ([@awy099-B66]).

According to the cholinergic hypothesis, there are deficiencies in the cholinergic pathways in Alzheimer's dementia which are associated with cognitive impairment ([@awy099-B19]). In experimental Alzheimer's dementia, low levels of soluble amyloid-β inhibit cholinergic synaptic function even before significant amyloid-plaque loads occur ([@awy099-B35]; [@awy099-B38]; [@awy099-B63]). The α4β2 nicotinic acetylcholine receptors (α4β2-AChRs) are widely expressed in the human brain, and decisively involved in cognitive functions such as attention, learning, and memory ([@awy099-B14]; [@awy099-B47]). Thus, PET imaging of cerebral α4β2-nAChRs might be sensitive to detect abnormalities early in the course of Alzheimer's dementia. In support of this assumption, post-mortem studies in patients with Alzheimer's dementia identified substantial decline in α4β2-nAChRs ([@awy099-B56]; [@awy099-B52]). High-affinity α4β2-nAChR PET radioligands, such as 2-^18^F-F-A85380, were developed to quantify α4β2-nAChR availability in the human brain *in vivo* ([@awy099-B34]). PET investigations in patients with Alzheimer's dementia and amnestic mild cognitive impairment, later converting to Alzheimer's dementia suggest that reductions of α4β2-nAChR availability are present early in the course of the disease and associated with cognitive dysfunction ([@awy099-B59]; [@awy099-B32]; [@awy099-B49]). In contrast, other PET/SPECT studies did not find any significant differences of α4β2-nAChR availability between mild Alzheimer's dementia and healthy controls or relationships to cognitive dysfunction ([@awy099-B16]; [@awy099-B45]). This has led to the ongoing controversy regarding the questions, whether there is a decrease of α4β2-nAChR availability in mild Alzheimer's dementia and whether this decrease is related to cognitive decline. The relatively slow kinetics of 2-^18^F-F-A85380 requiring acquisition times up to 7 h for full kinetic modelling, limits its use for clinical applications ([@awy099-B59]). Recently, a new generation of α4β2-nAChR-specific PET radioligands, such as (−)-^18^F-flubatine, or ^18^F-AZAN and ^18^F-nifene, has been developed, showing high specific binding combined with fast kinetics ([@awy099-B9]; [@awy099-B26]; [@awy099-B70]). We have previously published the pharmacokinetic modelling results of (−)-^18^F-flubatine PET in healthy male subjects and identified favourable characteristics, i.e. (i) high brain uptake; (ii) fast kinetics; (iii) high stability; (iv) ability to describe α4β2-nAChR binding by a simple one-tissue-compartment model within 90 min for all regions of interest; and (v) proven safety and tolerability ([@awy099-B61]; [@awy099-B58]). In the current PET study, (−)-^18^F-Flubatine has been applied in patients with Alzheimer's dementia in order to quantify alterations of α4β2-nAChRs. We hypothesize that (i) in mild Alzheimer's dementia compared with healthy controls, α4β2-nAChR availability is lower in distinct areas of the brain, especially those involving the fronto-temporo-parietal cortices and basal forebrain; and (ii) in Alzheimer's dementia, there is a relationship between α4β2-nAChR availability and domain-specific cognitive performance.

Materials and methods
=====================

This is a proof-of-concept, first-in-human study of prospectively recruited patients with Alzheimer's dementia and healthy, elderly controls, using the recently developed radioligand (−)-^18^F-flubatine to investigate the α4β2-nAChR availability. In the previously published first part of this PET study, the kinetic modelling characteristics of (−)-^18^F-flubatine have been described ([@awy099-B58]).

Cohorts
-------

Fourteen patients with mean (range) age 75.1 (58--83) years, with mild Alzheimer's dementia from the Department of Psychiatry, University Hospital Leipzig were compared with 15 healthy control subjects with mean (range) age 71.3 (63--77) years. To avoid possible effects not related to disease pathophysiology, patients with Alzheimer's dementia and healthy controls were matched for age, sex and education ([@awy099-B42]; [@awy099-B44]; [@awy099-B21]). To achieve this patients and healthy controls were derived from a larger, unmatched study population (*n* = 41). All study subjects were non-smokers, drug-naïve for cholinesterase inhibitors, drug-free for any kind of centrally acting medication and had no history of neurological or psychiatric disorder other than Alzheimer's dementia. The diagnosis of mild, probable Alzheimer's dementia was made according to the NINCDS-ADRDA criteria characterized by progressive cognitive decline (in accordance with DSM-IV criteria for dementia), and a score of 1 on the Clinical Dementia Rating scale (CDR) and 24.0 ± 2.6 mean ± standard deviation (SD) on the Mini-Mental State Examination (MMSE). Healthy controls (CDR = 0) were recruited by newspaper advertisement and were required to achieve psychometric test results within 1 SD of the mean of reference normative data as provided by standard test manuals.

All subjects and patients gave written informed consent. The study was performed according to the 1964 Declaration of Helsinki and subsequent revisions, and was approved by the local ethics committee and the other competent authorities in Germany.

Neuropsychological assessment
-----------------------------

This neuropsychological assessment included the full CERAD-Plus test battery (Category fluency, Letter fluency, Boston Naming Test, MMSE, Wordlist immediate and delayed recall; Wordlist savings score; Trail Making Test A and B), the subtests Logical Memory and Digit Span from the revised Wechsler Memory Scale, the Alters-Konzentrations-Test (AKT-G; a standardized geriatric cancellation test measuring attention/concentration), the Clock Drawing Test, the Multiple-Choice Vocabulary Intelligence Test ([@awy099-B46]; [@awy099-B65]; [@awy099-B24]; [@awy099-B37]; [@awy099-B22]), and the Geriatric Depression Scale (GDS; [@awy099-B71]). Raw scores were converted to Z-scores by means of the normative data provided in the corresponding test manuals. Z-scores of relevant subtests were averaged to calculate five cognitive domains of interest, that are attention (AKT-G, digit span forward); executive function/working memory (Trail-Making-Test-B/A, letter fluency, digit span backward); visuospatial abilities (CERAD: visuoconstruction copy and recall), language (Boston Naming Test, category fluency); and episodic memory (CERAD: wordlist immediate and delayed recall, wordlist savings, visuoconstruction savings; WMS-R: Logical Memory immediate and delayed recall).

PET imaging procedures, kinetic modelling and analysis
------------------------------------------------------

(−)-^18^F-flubatine was synthesized according to a recently published fully automated and good manufacturing practice compliant procedure ([@awy099-B51]). The specific activity of (−)-^18^F-flubatine was ∼1500 GBq/µmol at the time of injection ([@awy099-B51]). PET data were obtained in 3D scanning mode with an ECAT Exact HR+ system \[Siemens/CTI, 63 slices, resolution 4.7 mm full-width at half-maximum (FWHM)\] after the injection 90 s continuous short infusion (10 ml solution) of a dose of ∼370 MBq (−)-^18^F-flubatine. Emission measurements consisted of one dynamic PET scan of 90 min (23 frames) and three subsequent scans (30 min, six frames each) starting at 2, 3 and 4 h post-injection, resulting in a total acquisition time of 270 min. Between the PET scans, starting after the first 90 min, patients and healthy controls were allowed to leave the PET system. PET data were corrected for scatter, attenuation (as estimated by means of a 10-min transmission scan acquired with three rotating ^68^Ge rod sources before the first emission scan), and radioactive decay, and reconstructed by ordered subset expectation maximization with 10 iterations and 16 subsets with a pixel size of 0.2574 × 0.2574 × 0.2425 cm. PET and blood data processing were performed as recently described in detail. In the current data analysis only 0 to 90 min dynamic data were used since kinetic data analysis has shown that analysis of 0 to 90 min dynamic data allows accurate quantification of all brain regions ([@awy099-B50]; [@awy099-B58]). In brief, tissue time activity curves from 0 to 90 min were used for kinetic analysis with a one-tissue compartment model to calculate the total distribution volume (V~T~). For SPM analysis we needed a voxel-based approach to compute the distribution volume V~T~. Thus, Logan's graphical analysis was applied on a voxel-wise basis to compute parametric images of V~T~. Approximately 35 arterial plasma samples were obtained per subject to create individual input functions for kinetic modelling. Metabolite analysis showed high stability *in vivo* with 90% untransformed parent compound at 90 min. Because of the low number of metabolites ([@awy099-B58]) and to avoid errors introduced by the metabolite correction, the results presented were computed without metabolite correction. As recently reported, the plasma protein binding was 15 ± 2% and did not differ significantly between patients with Alzheimer's dementia and healthy controls ([@awy099-B50]). *K*~1~ is the delivery rate constant and equals the product of blood flow and extraction fraction of the radiotracer. As the extraction fraction is high for this tracer ([@awy099-B58]), *K*~1~ was used as brain blood flow surrogate and indirect measure of neurodegeneration. *K*~1~ values were computed from the PET data within a composite volume of interest, comprising the frontal, temporal, and parietal cortices, regions typically affected in Alzheimer's dementia.

It could be possible that the specific binding portion of the distribution volume (V~S~)---not contaminated by non-displaceable binding---is more appropriate as receptor parameter for group comparisons between patients with Alzheimer's dementia and healthy controls. To account for interindividual variability in the non-displaceable distribution volume (V~ND~), V~S~ was calculated using the corpus callosum as part of the white matter as pseudo-reference region, assuming that V~T~corpus callosum equals V~ND~ in all brain regions, as follows: V~S~ = V~T~target region − V~T~corpus callosum. Since the corpus callosum is the region of the brain with lowest V~T~ and mostly devoid of α4β2-nAChRs ([@awy099-B8]), it was used as pseudo-reference region as published previously by α4β2-nAChR PET using 2-^18^F-F-A85380 ([@awy099-B59]; [@awy099-B42]; [@awy099-B32]; [@awy099-B49]). The use of the corpus callosum as pseudo-reference region for between-group comparisons was justified, because V~T~ within the corpus callosum in Alzheimer's dementia and healthy controls was similar and did not differ significantly. To account for morphometric changes that are present in Alzheimer's dementia and elderly healthy controls ([@awy099-B54]) and which may affect the individual volume of interest analysis of the V~T~ data, additional approaches were carried out: the individual volumes of interest used to assess V~T~ were accounted for true grey matter density (GMD) as assessed by voxel-based analysis of MRI. Thus, GMD mask-weighted V~T~ values (V~T~GMDW) were determined. Further, a partial volume effect (PVE) correction on the dynamic PET data, i.e. separately on each acquired time frame, was applied. For that purpose, we used the region-based voxel-wise (RBV) method as previously proposed and implemented ([@awy099-B69], [@awy099-B68]). The PVE-corrected tissue time activity curves from 0--90 min were used for kinetic analysis with a one-tissue compartment model to calculate the PVE-corrected total distribution volume V~T~PVEC.

MRI procedures and analysis
---------------------------

Subjects received 3 T brain MRI (Magnetom Trio, Siemens Healthcare) mainly to preclude relevant pathological findings not related to Alzheimer's dementia, and to determine the degree of medial temporal lobe atrophy and the extent of white matter lesions based on either the Scheltens or Fazekas Scale ([@awy099-B17]; [@awy099-B62]). The imaging protocol included a T~1~-weighted magnetization prepared rapid gradient echo 3D sequence (MPRAGE; repetition time = 2130 ms, echo time = 3.03 ms, inversion time = 1200 ms, matrix 256 × 256 × 256, pixel bandwidth 130 Hz) and a transverse T~2~-weighted turbo spin echo sequence. The MRI data were preprocessed using the VBM8 toolbox (<http://dbm.neuro.uni-jena.de/vbm/download/>) for SPM8 (Wellcome Trust Centre for Neuroimaging, UCL, London, UK) and MATLAB 7.13 (The MathWorks Inc., Natick, MA, USA). The default settings were used while correcting for bias-field inhomogeneity and generating the tissue probability maps for white and grey matter. Non-linear normalization was carried out using the Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra (DARTEL) approach ([@awy099-B2]). The resulting modulated (corrected for individual brain size) and spatially normalized data were smoothed using an 8 mm FWHM Gaussian kernel.

To denote the modulated and normalized grey matter probability values, the GMD was used. Forebrain analysis of GMD and V~T~ in the basal forebrain was carried out by extracting a binary mask of the basal forebrain cholinergic system (Ch1-3, Ch4) provided by the Anatomy Toolbox in SPM ([@awy099-B15]; [@awy099-B73]). The averaged GMD and averaged V~T~ inside the mask were calculated. Within the model, we masked the GMD maps by a threshold of 0.1 (absolute thresholding). Values of GMD as assessed by VBM within the hippocampus and basal forebrain in Alzheimer's dementia were compared with healthy controls.

Volume of interest and SPM analysis of PET data
-----------------------------------------------

The individual MRI datasets of patients and healthy subjects were spatially reoriented onto a standard brain dataset similar to Talairach space. For volume of interest analysis, cortical, subcortical, white matter and cerebellar regions of interest, except basal forebrain, were manually drawn bilaterally on three consecutive transversal slices (if necessary two or four slices) of the reoriented T~1~-weighted-MPRAGE datasets using PMOD software (PMOD Technologies). The thickness of the MRI slices was transformed to 2.5 mm to enlarge the volume encompassed by the chosen consecutive slices as described previously in detail ([@awy099-B58]). The localizations of individually drawn regions of interest for the volume of interest analysis of the PET data are exemplified in the MRI of one study subject ([Supplementary material](#sup1){ref-type="supplementary-material"} and [Supplementary Fig. 1](#sup1){ref-type="supplementary-material"}). Voxel-based analysis was performed using SPM8. V~T~ maps were spatially normalized onto the individual 3D T~1~ MPRAGE MRI and smoothed with 8 mm FWHM on a Gaussian filter.

Statistical analyses
--------------------

Because this is a first-in-human PET investigation in Alzheimer's dementia using the recently developed radioligand (−)-^18^F-flubatine and thus because of the paucity of data and the relatively small number of study cohorts, this study is exploratory in nature. Statistical analyses were performed with IBM SPSS statistic software, version 24. All variables were tested for normal distribution using the Kolmogorov-Smirnov test. For group comparisons of clinical and cognitive data of Alzheimer's dementia and healthy controls, two-tailed *t*-tests were performed (significance at *P* \< 0.05). For group comparisons and correlation analyses regarding the volume of interest-based PET and MRI data, significance was regarded as relevant following correction for multiple testing using the false discovery rate (FDR) correction method (*P* \< 0.05~corrected~; [@awy099-B5]). For volume of interest analyses of PET data, the right and left side of the brain were pooled after ruling out significantly relevant right/left asymmetries (paired *t*-test; significance at *P* \< 0.05~corrected~). Group comparisons (Alzheimer's dementia versus healthy controls) of PET and MRI data were carried out applying ANCOVA (adjusted for age and sex). For volume of interest analysis, five brain regions with known Alzheimer's dementia pathology were selected *a priori*, such as the mean cortex (i.e. the frontal, lateral temporal, mesial temporal and parietal cortices), the basal forebrain, the frontal, mesial temporal (hippocampus), and parietal cortices (significance at *P* \< 0.05~corrected~; [@awy099-B32]; [@awy099-B4]). For *post hoc* volume of interest analysis of---at most---12 additional brain regions, a *P* \< 0.004~uncorrected~ (*P* \< 0.05~corrected~) was accepted as significant. For *post hoc*, exploratory SPM analysis of V~T~ parametric images, differences were accepted as significant at *P* \< 0.001~uncorrected~, extent threshold k = 5 voxels. Following correction for multiple comparisons, *P* \< 0.05 \[family-wise error (FWE)-, FDR-, or set level-corrected\] was considered as highly significant ([@awy099-B20]; [@awy099-B10]; [@awy099-B42]).

To determine whether there were age-, sex-, or education-related effects on α4β2-nAChR availability within each cohort (healthy controls or Alzheimer's dementia), volume of interest-based analyses of V~T~ (or V~S~) between study cohorts regarding sex were carried out using an unpaired two-tailed *t*-test (significance at *P* \< 0.002~uncorrected~; *P* \< 0.05~corrected~). Correlation analyses between V~T~ (or V~S~) and education or age in each study cohort were performed using one-sided Pearson's correlation test (significance at *P* \< 0.002~uncorrected~; *P* \< 0.05~corrected~).

Volume of interest-based correlation analyses between PET data in distinct cortical volumes of interest and neuropsychological Z-scores characterizing the five cognitive partial functions (episodic memory, executive function/working memory, attention, language, and visuospatial abilities) were carried out in the Alzheimer's dementia cohort only, using partial correlation analysis (adjusted for education and sex). Significance was accepted at *P* \< 0.05~corrected~. According to review data from the literature, brain regions that are considered to be most relevant for each of the five cognitive domains, were identified as *a priori* selected volumes of interest. *A priori* selected volumes of interest were as follows: episodic memory (frontal, mesial temporal, parietal cortices and basal forebrain), executive function/working memory (frontal and parietal cortices), language (frontal and temporal cortices), attention (frontal and parietal cortices), and visuospatial function (parietal and occipital cortices; [@awy099-B12]; [@awy099-B18]). To explore correlations between episodic memory and PET data within subregions of the mesial temporal cortex, *post hoc* volume of interest-based correlation analysis between episodic memory and α4β2-nAChR availability within hippocampus and amygdala was carried out.

*Post hoc*, exploratory, voxel-based correlation analyses between parametric images of V~T~ and the five cognitive domains (Z-scores) in Alzheimer's dementia were performed, and an exploratory *P* \< 0.001~uncorrected~, extent threshold of k = 5 voxels was considered significant. Clusters surviving FWE, FDR, or set-level-correction at *P* \< 0.05 were accepted as highly significant ([@awy099-B20]; [@awy099-B10]; [@awy099-B42]).

Results
=======

Study subjects
--------------

Patients with Alzheimer's dementia and healthy controls did not differ significantly from each other in education (13.1 ± 2.2 versus 13.8 ± 1.5 years; *P* = 0.378), age (75.1 ± 6.2 versus 71.3 ± 4.7 years; *P* = 0.071), and sex distribution (Alzheimer's dementia: four males/10 females, healthy controls: eight males/seven females; *P* = 0.264). MMSE was significantly lower in Alzheimer's dementia compared with healthy controls (24.0 ± 2.6 versus 28.4 ± 0.9, *P* \< 0.001). Patients with Alzheimer's dementia, compared with healthy controls, had significantly higher GDS scores (7.4 ± 3.6 versus 3.3 ± 2.2, *P* \< 0.001) indicating mild depressive symptoms. In Alzheimer's dementia, compared with healthy controls, Scheltens scores were significantly higher (1.4 ± 1.0 versus 0.7 ± 0.5, *P* = 0.025) implying atrophic, hippocampal changes. In Alzheimer's dementia, compared with healthy controls, in both cohorts, Fazekas scores were mildly increased, indicating mild white matter hyperintensities and thus mild small vessel disease. In Alzheimer's dementia, compared with healthy controls, there was a trend for higher Fazekas scores, without reaching significance (deep white matter hyperintensities: 1.3 ± 0.7 versus 0.8 ± 0.6, *P* = 0.053; periventricular white matter hyperintensities: 1.3 ± 0.8 versus 0.8 ± 0.7, *P* = 0.074) ([Supplementary material](#sup1){ref-type="supplementary-material"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Compared with healthy controls, patients with Alzheimer's dementia showed significantly lower Z-scores in most cognitive tests, derived from the cognitive test battery, resulting in significantly lower Z-scores in four out of the five cognitive domains. Z-scores were mostly reduced in Alzheimer's dementia regarding visuospatial function and episodic memory followed by language and executive function/working memory (*P* \< 0.001). The Z-score of attention did not significantly differ between Alzheimer's dementia and healthy controls (*P* = 0.161) ([Table 1](#awy099-T1){ref-type="table"} and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Table 1Impaired cognitive domains in patients with Alzheimer's dementia compared with healthy controlsZ-scores[^a^](#tblfn2){ref-type="table-fn"}Alzheimer's dementiaHealthy controlst/F*P*-valueAttention[^b^](#tblfn3){ref-type="table-fn"}0.31 (1.04)0.78 (0.63)−1.450.161Executive function/working memory−0.51 (0.89)0.44 (0.80)−3.02**\<0.001**Language−1.09 (1.00)0.59 (0.51)−5.75**\<0.001**Visuospatial abilities−2.05 (1.11)−0.19 (0.82)−5.13**\<0.001**Episodic memory−1.76 (0.80)0.32 (0.70)−7.51**\<0.001**[^2][^3][^4][^5]

Image data of neurodegeneration
-------------------------------

Kinetic modelling of the PET data indicated in Alzheimer's dementia, compared with healthy controls, significantly lower *K*~1~ values within the composite volume of interest of the fronto-temporo-parietal cortices (0.31 ± 0.04 versus 0.35 ± 0.04; −11%; *P* = 0.006; *P* \< 0.05~corrected~). VBM analysis revealed that in Alzheimer's dementia, compared with healthy controls, there was significantly lower grey-matter density in the hippocampus (right/left side pooled; 0.54 ± 0.11 versus 0.66 ± 0.06; −18%; *P* \< 0.001; *P* \< 0.05~corrected~) and basal forebrain (0.29 ± 0.05 versus 0.36 ± 0.03; −19%; *P* \< 0.001; *P* \< 0.05~corrected~).

Asymmetry of α4β2-nAChR availability within the brain
-----------------------------------------------------

Following correction for multiple comparisons, no significant asymmetric differences within the brain of Alzheimer's dementia or healthy controls for any quantitative PET parameters of α4β2-nAChR availability were found.

Effect of education, sex and age on α4β2-nAChR availability
-----------------------------------------------------------

Following correction for multiple comparisons, in both cohorts there were no significant correlations between education or age and V~T~ (or V~S~) within any of the 18 brain regions that were studied. Furthermore, no sex-related differences of V~T~ (or V~S~) were found.

α4β2-nAChR availability in Alzheimer's dementia and healthy controls
--------------------------------------------------------------------

Parametric images of the V~T~ exemplify typical regional α4β2-nAChR availability within the brain of one representative patient with Alzheimer's dementia and one healthy control subject, i.e. high within the thalamus, moderate within the striatum, brainstem, cerebellum and white matter centrum semiovale, low within the neocortex and limbic regions and very low within the corpus callosum. Compared to the healthy control subject, lower cortical, subcortical and cerebellar V~T~ in the patient with Alzheimer's dementia can be visualized ([Fig. 1](#awy099-F1){ref-type="fig"}). ANCOVA of volume of interest data revealed that in Alzheimer's dementia, there was significantly lower V~T~ in four of the five *a priori* selected brain regions reaching significance within the composite volume of interest including fronto-temporo-parietal cortices (mean cortex; −5%; *P* = 0.015; *P* \< 0.05~corrected~), within the frontal cortex (−5%; *P* = 0.020; *P* \< 0.05~corrected~), hippocampus as part of the mesial temporal cortex (−10%; *P* = 0.001; *P* \< 0.05~corrected~), and basal forebrain (−10%; *P* = 0.003; *P* \< 0.05~corrected~; [Table 2](#awy099-T2){ref-type="table"}). For exploratory *post hoc* analyses, in Alzheimer's dementia, there was significantly lower V~T~ within the right anterior cingulate cortex (−3%; *P* = 0.028; *P* \< 0.05~uncorrected~), thalamus (−9%; *P* = 0.011; *P* \< 0.05~uncorrected~), pons/midbrain (−7%; *P* = 0.027; *P* \< 0.05~uncorrected~), cerebellar cortex (−6%; *P* = 0.031; *P* \< 0.05~uncorrected~), and white matter centrum semiovale (−1%; *P* = 0.021; *P* \< 0.05~uncorrected~), although none of those *post hoc* comparisons remained significant after correction for multiple comparisons. Table 2Reduced α4β2-nAChR availability (V~T~) in Alzheimer's dementia compared with healthy controls using volume of interest analysisV~T~Alzheimer's dementia (*n* = 14)Healthy controls (*n* = 15)Change of AD compared with HC (%)*t*/*FP-*valueMeanSDMeanSD**Mean cortex**[^a^](#tblfn5){ref-type="table-fn"}8.691.009.180.53−54.25**0.015Frontal cortex**[^a^](#tblfn5){ref-type="table-fn"}8.771.099.260.62−53.93**0.020**Lateral temporal cortex8.610.988.950.46−43.300.037Mesial temporal cortex8.591.079.370.59−85.290.006**Hippocampus**[^a^](#tblfn5){ref-type="table-fn"}8.941.239.940.67−107.62**0.001**Amygdala9.131.219.600.82−51.300.297**Parietal cortex**[^a^](#tblfn5){ref-type="table-fn"}8.791.079.140.65−42.590.075Occipital cortex8.050.888.030.3701.790.175**Basal forebrain**[^a^](#tblfn5){ref-type="table-fn"}7.291.488.081.02−106.15**0.003**Anterior cingulate cortex8.920.989.240.82−33.580.028Posterior cingulate cortex9.070.989.270.69−20.910.451Caudate nucleus9.961.2910.220.82−30.650.588Putamen11.511.3811.400.8110.660.588Thalamus23.113.3725.463.16−94.530.011Pons/midbrain10.351.2311.130.87−73.620.027Cerebellar cortex11.901.4912.710.80−63.480.031Corpus callosum5.810.835.850.59−11.390.268White matter centrum semiovale10.011.5310.111.09−13.870.021[^6][^7][^8]

![**Parametric images of α4β2-nAChR availability (V~T~) in a patient with Alzheimer's dementia and a healthy control subject.** Parametric images of the V~T~ co-registered to individual MRI (transaxial views) exemplify the pattern of regionally distinct α4β2-nAChR availability in one representative patient with Alzheimer's dementia (*top*; male, aged 75 years, MMSE = 25, CDR = 1) and one healthy control subject (*bottom*; female, aged 71 years, MMSE = 28, CDR = 0). In the Alzheimer's dementia patient, compared with the healthy control subject, widespread decrease of α4β2-nAChR availability (V~T~) within the cortex and thalamus was observed. As indicated by the pseudo-coloured bar, V~T~ values range from low (blue) to high (red).](awy099f1){#awy099-F1}

Volume of interest analysis of V~S~ data revealed very similar findings as obtained by analysis of V~T~. In Alzheimer's dementia, there was widespread lower V~S~ reaching significance within four of the five *a priori* selected brain regions such as the mean cortex (−14%, *P* = 0.009, *P* \< 0.05~corrected~), frontal cortex (−13%, *P* = 0.016, *P* \< 0.05~corrected~), hippocampus as part of the mesial temporal cortex (−23%, *P* = 0.002, *P* \< 0.05~corrected~), and basal forebrain (−34%, *P* = 0.019, *P* \< 0.05~corrected~). For *post hoc* selected brain regions, V~S~ was significantly lower within the anterior cingulate cortex (−8%, *P* = 0.039; *P* \< 0.05~uncorrected~), within the thalamus (−12%, *P* = 0.021; *P* \< 0.05~uncorrected~) and the centrum semiovale in the white matter (−2%, *P* = 0.030; *P* \< 0.05~uncorrected~), although those *post hoc* findings for group comparisons did not remain significant after correction for multiple comparisons ([Supplementary material](#sup1){ref-type="supplementary-material"} and [Supplementary Table 3](#sup1){ref-type="supplementary-material"}).

Compared with healthy controls, in Alzheimer's dementia, there was significantly lower V~T~GMDW and V~T~PVEC within similar *a priori* selected cortical brain regions, as found by between-group comparisons for V~T~ and V~S~ measures. In contrast to V~T~ (and V~S~) measures, however, for V~T~GMDW and V~T~PVEC, following correction for multiple comparisons, significance in those *a priori* regions was reached only within the hippocampus and basal forebrain. In Alzheimer's dementia, compared with healthy controls, per cent reductions of V~T~GMDW were the lowest ([Supplementary material](#sup1){ref-type="supplementary-material"}, [Supplementary Tables 4](#sup1){ref-type="supplementary-material"} and [5](#sup1){ref-type="supplementary-material"}).

The explorative *post hoc* SPM analysis supported the findings from the volume of interest analyses, although significant clusters within the cortical brain regions typically affected by Alzheimer's dementia pathology were small. In Alzheimer's dementia, there were clusters with significantly lower V~T~ in the neocortex especially within the *a priori* defined brain regions such as the fronto-temporo-parietal cortices, the right hippocampus, and also within the cingulate cortex (*P* \< 0.001~uncorrected~; extent threshold k = 5 voxels; *P* \< 0.05~set-level\ corrected~; [Fig. 2](#awy099-F2){ref-type="fig"} and [Table 3](#awy099-T3){ref-type="table"}). Table 3Lower α4β2-nAChR availability (V~T~) in patients with Alzheimer's dementia compared with healthy controls using SPM analysisSPM region[^a^](#tblfn8){ref-type="table-fn"}, Alzheimer's dementia \< healthy controlsSide of the brainCluster size[^b^](#tblfn10){ref-type="table-fn"}Coordinates[^c^](#tblfn11){ref-type="table-fn"}, mm (*x*, *y*, *z*)*T-*score[^d^](#tblfn12){ref-type="table-fn"}Z-score[^e^](#tblfn13){ref-type="table-fn"}*P*-value, uncorrected[^f^](#tblfn14){ref-type="table-fn"}**Frontal lobe**Frontal_Inf_TriL37−502284.093.54\<0.0001Frontal_SupL28−2058143.843.37\<0.0001Frontal_Med_OrbL93−264−43.763.31\<0.0001Frontal_Sup_MedialR/L26483.653.240.001Frontal_Sup_OrbL19−2244−143.623.210.001Frontal_MidR8385803.563.170.001**Temporal lobe**Fusiform, lingualR928−44−103.613.210.001**Limbic lobe**HippocampusR2816−14−163.763.32\<0.0001**Parietal lobe**Precuneus, calcarineL115−28−58164.143.58\<0.0001**Occipital lobe**Cuneus, precuneusR1712−76423.813.35\<0.0001[^9][^10][^11][^12][^13][^14][^15][^16]

![**Reduced α4β2-nAChR availability (V~T~) in Alzheimer's dementia compared with healthy controls using SPM analysis.** Exploratory *post hoc* SPM analysis for the comparison of V~T~ parametric images in Alzheimer's dementia and healthy controls. Coloured clusters projected into transaxial slices of a standard MRI brain indicate significantly lower V~T~ in patients with Alzheimer's dementia compared with healthy controls, especially within the fronto-temporo-parieto cortices, and limbic regions (parahippocampus, posterior cingulate cortex). ANCOVA for group comparisons (adjusted for age and sex). Significance at *P* \< 0.001~uncorrected~; k = 5 voxels; *P* \< 0.05~set-level\ corrected~.](awy099f2){#awy099-F2}

Relationship between α4β2-nAChR availability and cognition in Alzheimer's dementia
----------------------------------------------------------------------------------

In patients with Alzheimer's dementia, the volume of interest-based correlation analyses revealed that there were significant positive associations between episodic memory and V~T~ within *a priori* defined brain regions such as the frontal (r = 0.78; *P* = 0.004), mesial temporal (r = 0.71; *P* = 0.01) and parietal cortices (r = 0.67; *P* = 0.02) (all *P* \< 0.05~corrected~; [Table 4](#awy099-T4){ref-type="table"}). There was no significant relationship between memory and V~T~ within the basal forebrain (r = 0.40; *P* = 0.13). Executive function/working memory and V~T~ showed significant positive associations within the frontal (r = 0.57; *P* = 0.04) and parietal cortices (r = 0.81; *P* = 0.002) (all *P* \< 0.05~corrected~; [Table 4](#awy099-T4){ref-type="table"}). There were no significant correlations between attention and V~T~ within the frontal and parietal cortices, between language and V~T~ within the frontal and temporal cortices, and between visuospatial function and V~T~ within the parietal and occipital cortices ([Table 4](#awy099-T4){ref-type="table"}). Table 4Volume of inteerest-based correlation analysis between cortical α4β2-nAChR availability (V~T~) within *a priori*-defined brain regions and five cognitive domains (Z-scores) in the Alzheimer's dementia cohortBrain regionBasal forebrainFrontal cortexMesial temporal cortexParietal cortexOccipital cortexdf = 8df = 8df = 8df = 8df = 8Episodic memory[^a^](#tblfn16){ref-type="table-fn"}r0.40**0.780.710.67**n.a.*P*0.1280.0040.0100.018n.a.Executive function / WM[^a^](#tblfn16){ref-type="table-fn"}rn.a.**0.57**n.a.**0.81**n.a.*P*n.a.0.041n.a.0.002n.a.Attention[^a^](#tblfn16){ref-type="table-fn"}rn.a.0.31n.a.0.41n.a.*P*n.a.0.190n.a.0.117n.a.Language[^a^](#tblfn16){ref-type="table-fn"}rn.a.0.020.25n.a.n.a.*P*n.a.0.4770.245n.a.n.a.Visuospatial function[^a^](#tblfn16){ref-type="table-fn"}rn.a.n.a.n.a.0.220.25*P*n.a.n.a.n.a.0.2720.245[^17][^18][^19]

Furthermore, exploratory, voxel-based correlation analyses identified significant positive correlations between memory dysfunction (Z-scores) and parametric images of reduced V~T~ in Alzheimer's dementia, especially within the left basal forebrain and left inferior frontal cortex (cluster level: *P* = 0.003~uncorrected~; *P* \< 0.05~FWE-corrected~), and furthermore, although not significant following correction for multiple comparisons, between the inferior temporal cortex, bilaterally, including the left parahippocampal gyrus ([Fig. 3](#awy099-F3){ref-type="fig"}A and [Table 5](#awy099-T5){ref-type="table"}). There were significant, positive correlations between impaired executive function/working memory and lower V~T~ within the left inferior temporal, right superior temporal and right parietal cortices in Alzheimer's dementia ([Fig. 3](#awy099-F3){ref-type="fig"}B and [Table 5](#awy099-T5){ref-type="table"}) (*P* \< 0.001~uncorrected~). There were significant, positive associations between impairment of attention and reduced V~T~ within the right frontal white matter, left thalamus, and left putamen in Alzheimer's dementia ([Fig. 3](#awy099-F3){ref-type="fig"}C and [Table 5](#awy099-T5){ref-type="table"}) (*P* \< 0.001~uncorrected~). Significant, positive associations between language and V~T~ within the right cerebellum (crus 1 and 2) in Alzheimer's dementia were found ([Table 5](#awy099-T5){ref-type="table"}, *P* \< 0.001~uncorrected~). No significant positive correlations between V~T~ and visuospatial function were identified. There were no significant, negative correlations between any cognitive domains and V~T~. Table 5Voxel-based correlation analyses demonstrate positive correlations between lower α4β2-nAChR availability (V~T~) and dysfunction of episodic memory, executive function/working memory, attention and language in patients with Alzheimer's dementiaSPM region[^a^](#tblfn19){ref-type="table-fn"}Side of the brainCluster size[^b^](#tblfn20){ref-type="table-fn"}Coordinates[^c^](#tblfn21){ref-type="table-fn"}, mm (*x*, *y*, *z*)*T-*score[^d^](#tblfn22){ref-type="table-fn"}Z-score^e^*P-*value[^f^](#tblfn24){ref-type="table-fn"}, uncorrected**Episodic memory**Frontal lobeFrontal_Inf_Orb[^g^](#tblfn25){ref-type="table-fn"}L1631−2018−2012.305.51\<0.0001Basal Forebrain[^g^](#tblfn25){ref-type="table-fn"}L−12−4−66.634.22\<0.0001Basal Forebrain[^g^](#tblfn25){ref-type="table-fn"}L−1210−126.534.19\<0.0001RectusR1841216−165.153.67\<0.0001Frontal_Sup_OrbR1824−225.123.66\<0.0001Rolandic_OperR10860−10105.043.62\<0.0001Rolandic_OperL14−48424.123.190.001Temporal lobeTemporal_InfL587−54−8−347.714.55\<0.0001Temporal_InfL−40−2−445.913.97\<0.0001FusiformL−288−445.133.66\<0.0001Temporal_Pole_MidR1323810−446.494.17\<0.0001Temporal_InfR34564−344.703.47\<0.0001Temporal_SupR10852−405.663.88\<0.0001Temporal_InfR666−14−304.103.180.001Limbic lobeParahippocampusL22−18−10−284.293.280.001ParahippocampusL−24−18−284.013.130.001**Executive function/working memory**Temporal lobeTemporal_InfL40−54−26−264.793.52\<0.001Temporal_InfL13−44−14−364.413.34\<0.001Parietal lobeSupramarginal/temporal_SupR3554−30184.373.32\<0.001**Attention**Frontal lobeWhite matterR139283645.853.77\<0.0001StriatumPutamenL13−261224.573.280.001ThalamusThalamusL8−16−1624.433.220.001**Language**CerebellumLobule VII_Crus2R76−84−384.183.22\<0.001Lobule VII_Crus1R610−82−264.073.16\<0.001[^20][^21][^22][^23][^24][^25][^26][^27]

![**Cognitive correlates of lower α4β2-nAChR availability (V~T~) in Alzheimer's dementia as assessed by SPM analysis.** Exploratory, linear correlation analyses using SPM identify significant positive correlations between parametric images of V~T~ and impairment of various cognitive domains (Z-scores) in Alzheimer's dementia as projected into a standard MRI brain and indicated by coloured clusters (significance at T \> 3.93; *P* \< 0.001~uncorrected~; k = 5 voxels). Memory dysfunction is positively correlated with V~T~ especially within the left basal forebrain and inferior frontal cortex (cluster-level: *P* = 0.003~uncorrected~; *P* \< 0.05~FWE-corrected~) and inferior temporal cortex and parahippocampus (**A**). There is a positive relationship between altered executive function/working memory and V~T~ within the left inferior temporal, right superior temporal and right parietal cortices (**B**). Impairment of attention is positively associated with lower V~T~ within the right frontal white matter, left thalamus, and left putamen (**C**). No significant negative correlations were found.](awy099f3){#awy099-F3}

*Post hoc* volume of interest-based correlation analysis between episodic memory and PET data within subregions of the mesial temporal cortex showed a trend for a positive correlation within the hippocampus and a significant, positive correlation within the amygdala ([Supplementary material](#sup1){ref-type="supplementary-material"}). As compared to V~T~, major findings for those correlations between cognition and additional PET parameters were similar, although the significance levels were lower ([Supplementary material](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Using novel (−)-^18^F-flubatine and PET, the availability of α4β2-nAChRs in the brain of non-smoking, cholinergic drug-naïve patients with mild Alzheimer's dementia was quantitatively investigated and compared with healthy controls. This was accomplished to answer the question whether there is lower α4β2-nAChR availability early in the course of Alzheimer's dementia and whether this α4β2-nAChR state is related to cognitive decline ([@awy099-B59]; [@awy099-B32]; [@awy099-B49]). PET analyses in Alzheimer's dementia reveal that there is a reduction of α4β2-nAChR availability in *a priori* defined multiple cortical brain regions as measured in absolute (V~T~) and relative quantitative parameters (V~S~). Regardless of the method used to quantify the α4β2-nAChR availability by kinetic modelling of PET data, brain regions typically affected by Alzheimer's dementia, such as the basal forebrain, hippocampus, and fronto-temporal cortices, demonstrate a deficiency. Regarding regional preferences of this deficiency, in Alzheimer's dementia, the α4β2-nAChR availability is mostly reduced in the hippocampus and basal forebrain, i.e. −10% and −10% in V~T~ and −23% and −34%, respectively, in V~S~. As V~S~ is proportional to the receptor density, the reduction of V~S~ in Alzheimer's dementia is a direct measure of the reduction of the α4β2-nAChR density. The lower per cent reduction of V~T~ (as compared to V~S~) reflects the additional non-displaceable distribution volume V~ND~ (i.e. V~ND~ = V~T~ − V~S~), which is, as assessed by V~T~corpus callosum, not different in Alzheimer's dementia and healthy controls ([@awy099-B28]). As exploratory *post hoc* volume of interest analysis suggests, though not significant following correction for multiple testing, there may be also lower α4β2-nAChR availability within additional brain regions such as the pons, thalamus, and cerebellar cortex in mild Alzheimer's dementia. If these adjunct findings are verified in future PET studies, in mild Alzheimer's dementia, diminutions of cholinergic α4β2-nAChRs may not be restricted to the basal forebrain-cortical and septohippocampal cholinergic projections, but may be present also within the pontine-thalamic-cortical projection system, possibly representing dysfunction of non-cholinergic, e.g. noradrenergic systems, known to express α4β2-nAChRs ([@awy099-B14]; [@awy099-B67]).

Our results strongly support and extend earlier PET/SPECT findings using first-generation, α4β2-nAChR-specific radioligands, such as 2-^18^F-F-A85380 or 5-^123^I-I-A85380. Those PET/SPECT studies detected lower α4β2-nAChR availability in mild-to-moderate Alzheimer's dementia only by relative quantitative measures ([@awy099-B48]; [@awy099-B59]; [@awy099-B32]; [@awy099-B49]). However, those results were not supported by other PET/SPECT imaging studies using the absolute quantitative measure V~T~ as outcome measure to assess α4β2-nAChR availability in mild Alzheimer's dementia, leading to an ongoing controversy ([@awy099-B16]; [@awy099-B45]). Conflicting results by prior PET/SPECT studies may not only be due to methodological differences how to quantify the α4β2-nAChR availability, but also due to clinical data variability, such as heterogeneity of dementia severity, presence of genetic risk factors, and differences in the age of onset of the disease.

In the present (−)-^18^F-flubatine PET study, significantly lower α4β2-nAChR availability in Alzheimer's dementia was found, which ranges from −5 to −10% for V~T~ and −13 to −34% for V~S~, differences that are smaller than expected from respective post-mortem studies ([@awy099-B56]; [@awy099-B52]). These findings are less surprising since most of the Alzheimer's dementia patients investigated in our PET study have only mild dementia and 13 of 14 (93%) have the most common form of late onset-type Alzheimer's dementia. Moreover, the post-mortem studies used ^3^H-nicotine, a radioligand that does not bind selectively to α4β2-nAChRs, as suggested by the presence of high- and low-affinity binding sites ([@awy099-B53]). Of interest and similar to our findings regarding α4β2-nAChRs, modest diminutions of brain acetylcholinesterase, vesicular acetylcholine transporters and glucose metabolism using PET/SPECT in (mild) late-onset Alzheimer's dementia, were reported, mainly present within the temporal cortex ([@awy099-B36]; [@awy099-B7]; [@awy099-B33]). These findings in late-onset Alzheimer's dementia were in contrast to more pronounced and widespread cortical defects in early-onset Alzheimer's dementia ([@awy099-B36]; [@awy099-B33]). The relatively small, mean between-group differences of α4β2-nAChR availability might also be due to variance in both cohorts, reflecting normal, interindividual differences, ageing-related effects, and/or compensatory changes in early Alzheimer's dementia ([@awy099-B16]; [@awy099-B31]). Of note, in mild Alzheimer's dementia, decrease of α4β2-nAChR availability is most pronounced in the mesial temporal cortex and basal forebrain where tau aggregations start ([@awy099-B72]). In this regard, recent experimental studies and a combined amyloid-β and α4β2-nAChR PET investigation in Alzheimer's dementia determined direct relationships between α4β2-nAChRs and tau or amyloid-β aggregations, hallmarks of Alzheimer's dementia pathology ([@awy099-B49]; [@awy099-B3]; [@awy099-B72]). Future clinical PET association studies using radioligands to quantitatively assess tau and/or amyloid-β aggregations and α4β2-nAChR availability in Alzheimer's dementia will highly improve the understanding of α4β2-nAChR pathophysiology, and help to develop novel drug therapies ([@awy099-B49]; [@awy099-B40]; [@awy099-B30]). As compared to ^18^F-FDG, which is currently used as clinical symptomatic disease PET biomarker of Alzheimer's dementia, and compared to tau PET tracers, which are currently tested in a similar regard, we see the potential advantage of (−)-^18^F-flubatine PET by delivering specific information on the integrity of the cholinergic system, potentially simplifying 'go' or 'no-go' decisions on specific cholinergic treatment ([@awy099-B55]). To investigate this feature, however, additional comparative PET tracer studies connected with clinical outcome readouts after treatment will be required.

Correlation analyses reveal that, in patients with Alzheimer's dementia, there is a strong relationship between impaired episodic memory and reduced α4β2-nAChR availability, especially within the fronto-temporo-parietal cortices and basal forebrain, such brain regions in which α4β2-nAChR diminutions are most pronounced in Alzheimer's dementia. The regional pattern of these associations, especially within the fronto-temporo-parietal cortices and basal forebrain, is in line with previous investigations ([@awy099-B12]). Thus, our PET findings strongly support and extend the cholinergic α4β2-nAChRs hypothesis for patients with mild Alzheimer's dementia, which has been challenged and revisited previously ([@awy099-B16]; [@awy099-B59]; [@awy099-B45]; [@awy099-B49]; [@awy099-B3]). To our knowledge, this is the first report to identify *in vivo* associations between α4β2-nAChR availability, especially within basal forebrain, fronto-temporo-parietal cortices, and parahippocampus and episodic memory in patients with mild Alzheimer's dementia.

There is a strong association (significant following correction for multiple comparisons) between altered executive function/working memory and lower α4β2-nAChR availability, within the *a priori* defined fronto-parietal cortices in Alzheimer's dementia. Further, results of *post hoc* exploratory SPM analysis suggest, however not significant following testing for multiple comparisons, that there might be an additional relationship between executive function/working memory and lower α4β2-nAChR availability with the temporal cortex. Findings of two α4β2-nAChR PET/SPECT studies in mild-to-moderate Alzheimer's dementia using 2-^18^F-F-A85380 or 5-^123^I-I-A85380 demonstrated associations between impaired executive function and lower α4β2-nAChR availability, especially within the frontal cortex, supporting our results in part ([@awy099-B13]; [@awy099-B49]). Thus, findings suggest that the *a priori* defined network comprised of the fronto-parietal cortices, being assumed to be mainly associated with executive function/working memory, might be extended to the temporal cortex if confirmed by future PET investigations ([@awy099-B39]; [@awy099-B23]; [@awy099-B3]; [@awy099-B6]).

There is no significant correlation between impaired attention and decreased α4β2-nAChR availability within the *a priori* selected brain regions, such as the frontal and parietal cortices using volume of interest analysis in Alzheimer's dementia. Exploratory SPM analysis suggests that, although not significant following correction for multiple comparisons, there may be a relationship between reduced α4β2-nAChR availability in frontal white matter and subcortical brain regions such as the thalamus and putamen and dysfunction of attention. The PET findings support the view that fronto-thalamic-striatal α4β2-nAChRs contribute to the functional cholinergic network of attention ([@awy099-B60]; [@awy099-B27]).

Exploratory SPM analysis suggests that there might be a relationship between dysfunction of language and lower α4β2-nAChR availability within the right cerebellar cortex (crus 1 and 2) in Alzheimer's dementia. Although not significant following correction for multiple comparisons, this finding is in agreement with results of a meta-analysis investigating the functional topography of the cerebellum and identifying lobule VI and VII and crus 1 within the right posterior cerebellum to be associated with language ([@awy099-B64]; [@awy099-B11]). There is no significant relationship between visuospatial dysfunction and regional α4β2-nAChR availability in Alzheimer's dementia, which is in line with findings of prior α4β2-nAChR PET/SPECT studies ([@awy099-B43]).

In both study cohorts, there were no associations between education or age and α4β2-nAChR availability, and no sex-related differences of the α4β2-nAChR availability. Although previously reported using α4β2-nAChR PET/SPECT, the lack of a relationship between age or sex and α4β2-nAChR binding in this PET study may be explained by the relatively small size of the study cohorts, the small age range in both cohorts, and by the fact that in Alzheimer's dementia, α4β2-nAChR availability is influenced by distinct neuropathology ([@awy099-B42]; [@awy099-B44]).

There are the following limitations. First, the clinical diagnostic criteria of Alzheimer's dementia (NINCDS-ADRDA), as used in this study, may lack accuracy. Enrichment of the Alzheimer's dementia group by biomarkers of amyloid pathology, like amyloid-β PET, was not approved by the regulatory authorities. Thus, our Alzheimer's dementia cohort might contain patients suffering from other forms of dementia. To reduce this risk, we investigated *K*~1~ PET data within fronto-temporo-parietal cortices as calculated by pharmacokinetic modelling from the (−)-^18^F-flubatine PET data. *K*~1~ of (−)-^18^F-flubatine is closely correlated to cerebral blood flow and may therefore serve as an indirect measure of the degree of neurodegeneration. Further, VBM analyses of grey matter density within the basal forebrain and hippocampus were carried out in Alzheimer's dementia and healthy controls. In Alzheimer's dementia, the *K*~1~ PET and VBM analyses concordantly showed signs of neurodegeneration in brain regions typically affected in Alzheimer's dementia, by that supporting the clinical diagnoses. Second, although we investigated only mild Alzheimer's dementia, atrophy-related partial volume effects affecting α4β2-nAChR PET data analysis may be present and should be taken into account. To minimize atrophy-related effects, irregular brain tissue-containing volumes of interest were defined based on the individual MRI after MRI/PET co-registration. Additionally, grey matter density mask-weighted V~T~ values and partial volume effect corrected V~T~ values were calculated for each subject. The pattern of regionally lower V~T~GMDW, V~T~PVEC and V~T~ in Alzheimer's dementia compared with healthy controls, was similar. Furthermore, for those PET parameters very close correlations between V~T~, V~T~GMDW, and V~T~PVEC and specific cognitive partial functions were found in Alzheimer's dementia. Therefore, a major effect of brain atrophy on these PET findings can be ruled out.

To summarize, in mild Alzheimer's dementia, there is a widespread reduction of cholinergic α4β2-nAChR availability especially within the hippocampus, fronto-temporal cortices, and basal forebrain, most pronounced within the mesial temporal cortex (hippocampus) and basal forebrain. Further, in Alzheimer's dementia, there is a relationship between networks of decreased α4β2-nAChR availability, especially within fronto-temporo-parietal cortices and basal forebrain and impairment of episodic memory, and within fronto-parietal cortices and impairment of executive function/working memory. This shows the potential of (−)-^18^F-flubatine as PET biomarker of cholinergic α4β2-nAChR vulnerability and specific cognitive decline. Thus, (−)-^18^F-flubatine might become a biomarker of progression of α4β2-nAChR neurodegeneration in Alzheimer's dementia. This hypothesis, however, needs to be proved by prospective, longitudinal PET investigations.
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α4β2-nAChR

:   α4β2 nicotinic acetylcholine receptor

GMD

:   grey-matter density

PVEC

:   partial volume effect correction

V~ND~

:   non-displaceable distribution volume

V~S~

:   specific binding part of the distribution volume

V~T~

:   distribution volume

[^1]: Osama Sabri, Philipp M. Meyer, Peter Schönknecht and Peter Brust contributed equally to this work.

[^2]: Degrees of freedom = 27.

[^3]: ^a^Z-scores are given as mean and standard deviation (in parentheses).

[^4]: ^b^ANCOVA was calculated for this variable to account for years of education as covariate.

[^5]: Unpaired two-tailed *t*-test for the comparison between Alzheimer's dementia and healthy controls; significance at *P* \< 0.05 (bold).

[^6]: ^a^*A priori* selected brain region with known Alzheimer's dementia pathology.

[^7]: ANCOVA for the comparison of V~T~ between Alzheimer's dementia and healthy controls (adjusted for age and sex), within five *a priori* defined cortical brain regions, such as mean cortex, frontal, mesial temporal (hippocampus), parietal cortices, and basal forebrain (in bold); significance at *P* \< 0.05~corrected~ (FDR correction according to Benjamini-Hochberg; in bold). Furthermore, exploratory *post hoc* analysis for 12 additional brain regions, significance at *P* \< 0.004~uncorrected~ (*P* \< 0.05~corrected~; FDR correction).

[^8]: AD = Alzheimer's dementia; HC = healthy controls.

[^9]: ^a^SPM regions of lower (−)-^18^F-flubatine distribution volume (V~T~) in patients with Alzheimer's dementia compared with healthy controls.

[^10]: ANCOVA for the comparison between Alzheimer's dementia and healthy controls with age and sex as covariates.

[^11]: ^b^Cluster size is expressed in 2 mm^3^ voxels.

[^12]: ^c^Location of the peak in the 3D stereotactic coordinates (*x*, *y*, *z*).

[^13]: ^d^Standardized *T*-scores.

[^14]: ^e^Standardized Z-scores.

[^15]: ^f^Significance was accepted at *P* \< 0.001~uncorrected~; extent threshold of k = 5 voxels, *P* \< 0.05~set-level\ corrected~, number of clusters = 13.

[^16]: L = left; MNI = Montreal Neurological Institute; R = right; SPM = Statistical Parametric Mapping.

[^17]: ^a^Partial correlations were calculated for this variable (corrected for education and sex).

[^18]: ^b^Bold coefficients represent significant correlations after controlling for multiple testing according to Benjamini-Hochberg (*P* \< 0.05~corrected~).

[^19]: df = degrees of freedom; n.a. = not applicable; r = correlation coefficient; WM = working memory.

[^20]: ^a^SPM regions of significant positive correlation between (−)-^18^F-flubatine distribution volume (V~T~) in patients with Alzheimer's dementia and episodic memory, executive function/working memory, attention and language (Z-scores). Linear correlation analysis in Alzheimer's dementia between V~T~ and distinct cognitive domains.

[^21]: ^b^Cluster size is expressed in 2 mm^3^ voxels.

[^22]: ^c^Location of the peak in the stereotactic coordinates.

[^23]: ^d^Standardized *T*-scores.

[^24]: ^e^Standardized Z-scores.

[^25]: ^f^Significance was accepted at *P* \< 0.001~uncorrected~; extent threshold of k = 5 voxels.

[^26]: ^g^Brain region with significance following correction for multiple comparisons at *P* = 0.003~uncorrected~, *P* \< 0.05~FWE-corrected~ (cluster-level).

[^27]: L = left; R = right; SPM = Statistical Parametric Mapping.
